Comparison of Two Ways of Administration of the Neuromuscular Blockade in Thoracic Surgical Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00018968

Enrollment

Registered

2019-10-10

Start date

2020-01-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular blockade

Interventions

Group 1: Continuous administration of Rocuronium, aiming a deep neuromuscular blockade (no answer to TOF-stimulation, number of twitches after PTC-stimulation between 1-5). When needed (for example b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - age over 18 years - elective thoracical surgery with resection of lung parenchyma (at least anatomical resection) - written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: - age under 18 years - known allergy to rocuronium sugammadex - severe kidney impairment (GFR under 30) - significant liver disfunction - neuromuscular disorders - BMI above 35 kg/m2 - current use of antiepileptic agents, lithium or medication containing quinine - refusal to participate and the absence of written informed consent

Design outcomes

Primary

Measure	Time frame
Rating of surgical conditions using a rating scale	—

Secondary

Measure	Time frame
- overall dose of administrated rocuronium (mg/kg/min Operation) - the need and total number of additional boli of rocuronium - time elapsed between end of neuromuscular blockade and end of the operation - TOF/PTC-Count at the end of the operation, need of administration of the reversing agent sugammadex, dosis of administrated sugammadex (mg/kg) - the ability of the surgeon to tell to which group the operated patient belongs - practicability of the continuous administration of the neuromuscular blockade	—

Measure

Time frame

- overall dose of administrated rocuronium (mg/kg/min Operation) - the need and total number of additional boli of rocuronium - time elapsed between end of neuromuscular blockade and end of the operation - TOF/PTC-Count at the end of the operation, need of administration of the reversing agent sugammadex, dosis of administrated sugammadex (mg/kg) - the ability of the surgeon to tell to which group the operated patient belongs - practicability of the continuous administration of the neuromuscular blockade

—

Countries

Germany

Contacts

Public ContactKatalin Szentannai

Klinik für Anästhesiologie, Intensivmedizin und SchmerztherapieKrankenhaus Martha-Maria Halle Dölau

katalin.szentannai@martha-maria.de0345-5591416

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026